China’s First TCM Law Excites Industry Looking For Cheer
This article was originally published in PharmAsia News
A long-awaited new law that could greatly enlarge the market for traditional Chinese medicines has prompted domestic drug makers in China to race to develop new products, but could it also hurt multinational drug companies in the country?
You may also be interested in...
A new commissioner has taken the reins at China's National Medical Products Administration, but the senior CCP official has so far given few clear indications about the changes he might bring.
Within a month of obtaining its global first approval in China, Hua Medicine's dorzagliatin is already available in hospitals. What was behind the successful launch of the first-in-class diabetes agent, what are reimbursement plans and how will local commercialization partner Bayer help? Founder and CEO Li Chen sits down to discuss these and other strategies.
Pfizer is facing a US lawsuit alleging wrongful termination and retaliation against a whistleblower after the company’s former director of Global Compliance Analytics discovered what he viewed to be potential violations in China of the US Foreign Corrupt Practices Act.